GlassScriptPhysician profile
Shail M Vyas
NPI 1548418627
$14,418.49
in general payments reported to CMS, 2019-2025
35 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,833 · 2020: $968 · 2021: $539 · 2022: $816 · 2023: $6,420 · 2024: $1,360 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,595 · Food and Beverage: $2,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,594.77 |
| Food and Beverage | $2,668.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $5,295.26 | 2019-2024 | |
| Stryker Corporation | $2,510.50 | 2020-2023 | Mako, Insignia |
| Si-Bone, INC. | $995.05 | 2023 | |
| Zimmer Biomet Holdings, INC. | $978.83 | 2019-2020 | |
| Curonix LLC | $882.59 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saxum Surgical, INC. | $817.04 | 2023-2025 | |
| Smith+Nephew, INC. | $610.92 | 2019-2024 | Acufex Director, Healicoil |
| Boston Scientific Corporation | $407.57 | 2022-2023 | Rhythmia Mapping System |
| Zynex Medical, INC. | $279.53 | 2025 | Nexwave |
| Bioventus LLC | $202.38 | 2019-2025 | Xcell, Exogen Ultrasound Bone Healing System, Supartz Fx Sodium Hyaluronate |
| Glaxosmithkline, LLC. | $186.22 | 2021-2022 | |
| Ermi LLC | $179.68 | 2019-2024 | |
| Miach Orthopaedics, INC. | $151.70 | 2023 | |
| Abbott Laboratories | $134.76 | 2019 | |
| Depuy Synthes Sales INC. | $110.94 | 2019-2025 | Orthovisc, Monovisc |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $110.25 | 2025 | |
| Biocryst US Sales Co., LLC | $99.71 | 2022 | |
| Nevro Corp. | $65.86 | 2021-2022 | |
| Fidia Pharma USA INC. | $47.79 | 2020-2025 | Triluron, Hymovis |
| Siemens Medical Solutions USA, INC. | $32.33 | 2025 | Immulite 1000 Immunoassay System |
| Kaleo, INC. | $31.46 | 2019-2021 | |
| Pacira Therapeutics, INC. | $29.99 | 2020 | |
| Radius Health, INC. | $29.87 | 2021 | |
| Micromed INC | $26.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.61 | 2021 | |
| Ge Healthcare | $24.14 | 2025 | |
| Linvatec Corporation | $22.22 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $20.25 | 2025 | |
| Genentech USA, INC. | $18.93 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.07 | 2025 | Dupixent |
| Horizon Therapeutics Plc | $17.77 | 2020 | |
| Optinose US, INC. | $17.06 | 2025 | |
| Nalu Medical, INC. | $16.35 | 2022 | |
| Avanos Medical | $15.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $6.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shail Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.